<SEC-DOCUMENT>0001437749-23-022787.txt : 20230809
<SEC-HEADER>0001437749-23-022787.hdr.sgml : 20230809
<ACCEPTANCE-DATETIME>20230809160807
ACCESSION NUMBER:		0001437749-23-022787
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20230809
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230809
DATE AS OF CHANGE:		20230809

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BioCardia, Inc.
		CENTRAL INDEX KEY:			0000925741
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				232753988
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38999
		FILM NUMBER:		231155165

	BUSINESS ADDRESS:	
		STREET 1:		320 SOQUEL WAY
		CITY:			SUNNYVALE
		STATE:			CA
		ZIP:			94085
		BUSINESS PHONE:		650-226-0123

	MAIL ADDRESS:	
		STREET 1:		320 SOQUEL WAY
		CITY:			SUNNYVALE
		STATE:			CA
		ZIP:			94085

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tiger X Medical, Inc.
		DATE OF NAME CHANGE:	20110616

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cardo Medical, Inc.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CLICKNSETTLE COM INC
		DATE OF NAME CHANGE:	20000823
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>bcda20230808_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:rr="http://xbrl.sec.gov/rr/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:bcda="http://www.bcda.com/20230809"><head>
	<title>bcda20230808_8k.htm</title>

	<!-- Generated by ThunderDome Portal - 8/9/2023 2:15:13 AM -->
<meta http-equiv="Content-Type" content="text/html" /></head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none">
<ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="d20238K" name="dei:AmendmentFlag">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d20238K" name="dei:EntityCentralIndexKey">0000925741</ix:nonNumeric>

</ix:hidden>
<ix:references>
<link:schemaRef xlink:href="bcda-20230809.xsd" xlink:type="simple" />
</ix:references>
<ix:resources>
<xbrli:context id="d20238K">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000925741</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2023-08-09</xbrli:startDate>
<xbrli:endDate>2023-08-09</xbrli:endDate>
</xbrli:period>
</xbrli:context>

<xbrli:context id="d20238K_StatementClassOfStockAxis_CommonStockParValue0001">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000925741</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcda:CommonStockParValue0001CustomMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2023-08-09</xbrli:startDate>
<xbrli:endDate>2023-08-09</xbrli:endDate>
</xbrli:period>
</xbrli:context>

<xbrli:context id="d20238K_StatementClassOfStockAxis_WarrantToPurchaseCommonStock">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000925741</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcda:WarrantToPurchaseCommonStockCustomMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2023-08-09</xbrli:startDate>
<xbrli:endDate>2023-08-09</xbrli:endDate>
</xbrli:period>
</xbrli:context>


</ix:resources>
</ix:header>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>UNITED STATES</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECURITIES AND EXCHANGE COMMISSION </b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Washington, D.C. 20549</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><b>FORM <ix:nonNumeric contextRef="d20238K" name="dei:DocumentType"><b>8-K</b></ix:nonNumeric></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CURRENT REPORT</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="d20238K" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate"><b>August 9, 2023</b></ix:nonNumeric></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:44.8039215686275%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:middle;width:101.1%;">
			<div style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20238K" name="dei:EntityRegistrantName"><b>BIOCARDIA, INC.</b></ix:nonNumeric></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:101.1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:69.5179738562092%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:middle;width:30.2%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20238K" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode"><b>Delaware</b></ix:nonNumeric></div>
			</td>
			<td style="vertical-align:middle;width:5%;">&#xa0;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:middle;width:30.2%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20238K" name="dei:EntityFileNumber"><b>0-21419</b></ix:nonNumeric></div>
			</td>
			<td style="vertical-align:middle;width:5%;">&#xa0;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:middle;width:30.2%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20238K" name="dei:EntityTaxIdentificationNumber"><b>23-2753988</b></ix:nonNumeric></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:30.2%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(State or other jurisdiction</div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">of incorporation)</div>
			</td>
			<td style="vertical-align:middle;width:5%;">&#xa0;</td>
			<td style="vertical-align:middle;width:30.2%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Commission</div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">File Number)</div>
			</td>
			<td style="vertical-align:middle;width:5%;">&#xa0;</td>
			<td style="vertical-align:middle;width:30.2%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(IRS Employer</div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Identification No.)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:39.2483660130719%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:middle;width:95.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20238K" name="dei:EntityAddressAddressLine1"><b>320 Soquel Way </b></ix:nonNumeric><br />
			<b><ix:nonNumeric contextRef="d20238K" name="dei:EntityAddressCityOrTown"><b>Sunnyvale</b></ix:nonNumeric>, <ix:nonNumeric contextRef="d20238K" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince"><b>California</b></ix:nonNumeric> <ix:nonNumeric contextRef="d20238K" name="dei:EntityAddressPostalZipCode"><b>94085</b></ix:nonNumeric></b></div>
			</td>
			<td style="vertical-align:middle;width:5.6%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:95.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Address of principal executive offices and zip code)</div>
			</td>
			<td style="vertical-align:middle;width:5.6%;">&#xa0;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Registrant</b>&#8217;<b>s telephone number, including area code: (<ix:nonNumeric contextRef="d20238K" name="dei:CityAreaCode"><b>650</b></ix:nonNumeric>) <ix:nonNumeric contextRef="d20238K" name="dei:LocalPhoneNumber"><b>226-0120</b></ix:nonNumeric></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">_____________________________________________</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><ix:nonNumeric contextRef="d20238K" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><ix:nonNumeric contextRef="d20238K" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><ix:nonNumeric contextRef="d20238K" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><ix:nonNumeric contextRef="d20238K" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-width: 1px; border-style: solid; border-color: black black rgb(0, 0, 0); vertical-align: middle; width: 16.5%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Title of each class</div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 16.6%; border-top: 1px solid black;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Trading Symbol(s)</div>
			</td>
			<td style="border-width: 1px; border-style: solid; border-color: black black rgb(0, 0, 0); vertical-align: middle; width: 16.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Name of each exchange on which registered</div>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 16.5%; border-left: 1px solid black; border-right: 1px solid black;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20238K_StatementClassOfStockAxis_CommonStockParValue0001" name="dei:Security12bTitle">Common Stock, par value $0.001</ix:nonNumeric></div>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:middle;width:16.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20238K_StatementClassOfStockAxis_CommonStockParValue0001" name="dei:TradingSymbol">BCDA</ix:nonNumeric></div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 16.6%; border-left: 1px solid black; border-right: 1px solid black;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">The <ix:nonNumeric contextRef="d20238K_StatementClassOfStockAxis_CommonStockParValue0001" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric> Capital Market</div>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 16.5%; border-left: 1px solid black; border-right: 1px solid black;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20238K_StatementClassOfStockAxis_WarrantToPurchaseCommonStock" name="dei:Security12bTitle">Warrant to Purchase Common Stock</ix:nonNumeric></div>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:middle;width:16.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20238K_StatementClassOfStockAxis_WarrantToPurchaseCommonStock" name="dei:TradingSymbol">BCDAW</ix:nonNumeric></div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 16.6%; border-left: 1px solid black; border-right: 1px solid black;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">The <ix:nonNumeric contextRef="d20238K_StatementClassOfStockAxis_WarrantToPurchaseCommonStock" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric> Capital Market</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:middle;width:100.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2 of this chapter) <ix:nonNumeric contextRef="d20238K" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&#xa0;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">&#xa0;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 2.02.</b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>Results of Operations and Financial Condition.</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">On August 9, 2023, BioCardia, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2023. A copy of the press release is furnished as Exhibit 99.1 to this report.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The information in this Item 2.02, including the Exhibit 99.1 attached hereto, is being furnished&#xa0;and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of such section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 9.01</b>&#xa0;&#xa0;&#xa0;<b>Financial Statements and Exhibits.</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(d) Exhibits</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:12.9%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Exhibit No.</b></div>
			</td>
			<td style="vertical-align:bottom;width:2.9%;">&#xa0;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:84.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Description</b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 12.9%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">99.1</div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">104</div>
			</td>
			<td style="vertical-align:middle;width:2.9%;">&#xa0;</td>
			<td style="vertical-align:middle;width:84.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_557356.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">BioCardia, Inc. press release dated August 9, 2023</span></a></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>
			</td>
		</tr>

</tbody></table>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&#xa0;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">&#xa0;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SIGNATURES</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:middle;width:35.1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>BIOCARDIA, INC.</b></div>
			</td>
			<td style="vertical-align:middle;width:64.9%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:35.1%;">&#xa0;</td>
			<td style="vertical-align:middle;width:64.9%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:middle;width:35.1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Peter Altman, Ph.D.</div>
			</td>
			<td style="vertical-align:middle;width:64.9%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:35.1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Peter Altman, Ph.D.</div>
			</td>
			<td style="vertical-align:middle;width:64.9%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:35.1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">President and Chief Executive Officer</div>
			</td>
			<td style="vertical-align:middle;width:64.9%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:35.1%;">&#xa0;</td>
			<td style="vertical-align:middle;width:64.9%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:35.1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date: August 9, 2023</div>
			</td>
			<td style="vertical-align:middle;width:64.9%;">&#xa0;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&#xa0;</div>
</div>
</div>
</div>


</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex_557356.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head>
	<title>ex_557356.htm</title>

	<!-- Generated by ThunderDome Portal - 8/9/2023 12:09:43 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><u>Exhibit 99.1</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>BIOCARDIA REPORTS SECOND QUARTER 2023 BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Sunnyvale, Calif.</b>&nbsp;&#8211;<b> August 9, 2023 -</b>&nbsp;<u>BioCardia, Inc.</u>&nbsp;[Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the second quarter of 2023 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2023 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management&#8217;s formal remarks, there will be a question-and-answer session.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#8220;We have followed the recent recommendation from our Data Safety Monitoring Board (DSMB) to pause enrollment of new patients in our autologous cell therapy trial for ischemic heart failure or BCDA-01, even as there were no treatment emergent safety issues reported, patients in aggregate appear to be showing clinical improvements, and enrollment had accelerated in recent months.&nbsp; We continue to randomize and monitor patients enrolled in this clinical study.&nbsp; Unblinded statistics and clinical consultants are reviewing the primary endpoint analysis and secondary outcome measures.&nbsp; Potential next steps in Q3 include discussions between the DSMB and the consultancies before BioCardia unblinds itself to the interim data,&#8221; said Peter Altman PhD.&nbsp; &#8220;As we work through this process for BCDA-01, we expect important milestones for our other clinical programs. We look forward to completion of enrollment for the roll-in cohort of the Phase III trial of our autologous cell therapy for patients with chronic myocardial ischemia or BCDA-02, as well as treatment of the first patients in the Phase I/II clinical trial of our allogeneic mesenchymal stem cell therapy for ischemic heart failure or BCDA-03.&nbsp; Business development is active around our Helix biotherapeutic delivery platform and in other areas, and we are working to close two meaningful deals by the end of the year.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>RECENT BUSINESS HIGHLIGHTS:</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>CardiAMP</b>&#174;<b> Autologous Cell Therapy for Patients with Ischemic Heart Failure (BCDA-01)</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The CardiAMP Cell Therapy Trial for Heart Failure is a Phase III, multi-center, randomized, double-blinded, sham-controlled study intended to include up to 260 patients. The Phase III pivotal trial, which was granted Breakthrough designation by the U.S. Food and Drug Administration (FDA), is designed to provide the primary support for the safety and efficacy of the CardiAMP Cell Therapy System for the treatment of heart failure with reduced ejection fraction (HFrEF).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On July 12, 2023, the planned Data Safety Monitoring Board (DSMB) meeting was held utilizing the adaptive statistical analysis plan reviewed by FDA in the second quarter. On July 24, 2023, the Company announced that the DSMB had completed its review and recommended that the Company pause the trial pending the one-year follow-up outcomes analysis for patients that have been treated and those that have been enrolled but not yet treated.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The DSMB reviewed an initial analysis of the unblinded data and concluded that the trial was unlikely to meet its primary FS composite endpoint, even though the prespecified criteria for termination of the trial had not been met. This initial analysis excluded patients who had not yet made it to 12-month follow-up. The DSMB also cited the slow rate of enrollment in the trial. Additional data was subsequently provided to the DSMB, which the Company understands included: (1) statistical analysis prepared strictly in accordance with the prespecified data review plan, which had not initially been provided to the DSMB, (2) analysis of health outcomes as measured by endpoints other than the six-minute walk, and (3) information on the increased enrollment rates across many clinical centers. After consideration of the additional data, the DSMB recommended that the Company pause enrollment of new patients pending the 12-month outcomes analysis for all patients, and that the Company continue to treat patients already enrolled in the trial. The DSMB also recommended that the data blind be preserved so that the trial may be continued following analysis of the 12-month follow-up data for all enrolled patients.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The blinded aggregate data for the 96 randomized patients with 12-month outcome measures available for the most recent DSMB review showed better-than-expected patient survival, improvement in mean six-minute walk distance, improvement in NYHA class, improvement in quality of life and improvement in left ventricular ejection fraction. The DSMB reported that there were no treatment emergent safety concerns in the study. An estimated additional 25 randomized patients will be included in final trial results should the trial not be restarted. This estimate includes 10 patients in the queue expected to be randomization in the trial in the next six weeks, nine randomized patients who have not yet reached the 12-month follow-up visit, and six patients who were unable to walk at 12 months due to other non-cardiac issues. Results will not be available until the last patient reaches their 12-month follow-up visit.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">An external statistics consultancy has completed a quality review on the primary endpoint interim data analysis provided to the DSMB to confirm they had accurate information. The company is working to enable this replicate analysis and the closed session DSMB information to be reviewed by a clinical consultant to make recommendations on next steps. If there are reasons to engage the DSMB, discussions between the DSMB and the unblinded consultants may take place. Once this quality review is completed by this external unblinded group, expected in the third quarter 2023, it is anticipated that a segregated BioCardia team will be unblinded to the data in order to provide strategic guidance for this program ahead. If the Company obtains material new information from this review, it will be shared publicly as appropriate.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In June 2023, the Company completed its submission of the CardiAMP Cell Therapy System to Japan&#8217;s Pharmaceutical and Medical Device Agency (PMDA) for a first formal consultation towards approval for the indication of ischemic heart failure with reduced ejection fraction (HFrEF) based on existing safety and efficacy data. In July, the formal consultation was reviewed and accepted by the PMDA for the consultation with some clarifying questions, which have been addressed. The PMDA consultation could take up to four months to schedule per their normal review process, although dates in September have been requested. Subsequent interactions with PMDA are expected. If approved, the CardiAMP Cell Therapy System has potential to be the first minimally invasive catheter-based cell therapy available in Japan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>CardiAMP</b>&#174;<b> Autologous Cell Therapy for Patients with Chronic Myocardial Ischemia (BCDA-02)</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The CardiAMP Cell Therapy Trial for Chronic Myocardial Ischemia is a Phase III, multi-center, randomized, double-blinded, controlled study intended to include up to 343 patients at up to 40 clinical sites. The Company expects to complete enrollment in the roll-in cohort of five patients in the fourth quarter of 2023 and begin the randomized phase of the trial. Planning for the randomization phase is already underway based on promising experience in the patients treated to date. Strategies of using the cell population analysis as a means to set patient dosing as opposed to excluding patients, and means to include more patients based on modifying baseline exclusion criteria, are under consideration to enable more rapid enrollment. Six additional centers are actively being onboarded.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>CardiALLO</b>&#8482;<b> Allogeneic Cell Therapy for Ischemic HFrEF (BCDA-03)</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In December 2022, the FDA approved the Company&#8217;s Investigational New Drug (IND) application to initiate a first-in-human Phase I/II clinical trial encompassing 69 patients with HFrEF treated with the Company&#8217;s allogeneic cells. Clinical grade cells have been manufactured at BioCardia and are ready for use with the Company&#8217;s proprietary delivery system, also manufactured at BioCardia. The first clinical center has finalized its clinical study agreement and received conditional IRB approval. Cellular preparation test runs at the clinical site and site activation visit is scheduled for this month. Patient enrollment is expected to begin in the third quarter.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">This study builds on three previous trials of mesenchymal stem cells (MSC) in ischemic heart failure using the Company&#8217;s proprietary Helix&#8482; delivery system encompassing 93 patients treated with culture expanded MSCs with no treatment emergent serious adverse events. Previous trial results showed compelling early signals for benefit that this trial is expected to build upon.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Allogeneic Cell Therapy for Acute Respiratory Distress Syndrome (BCDA-04)</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company&#8217;s Allogeneic Cell Therapy Trial for Acute Respiratory Distress Syndrome (ARDS) has been deprioritized to focus current financial resources on other programs. This decision was based on the greatly reduced population of patients with acute respiratory distress secondary to COVID. When resources permit, BioCardia intends to expand the current indication to a broader ARDS population beyond COVID and to other pulmonary indications.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Helix</b><b><sup style="vertical-align:top;line-height:120%;">TM</sup></b><b> Biotherapeutic Delivery System</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">BioCardia&#8217;s Helix Biotherapeutic Delivery System (Helix) delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart. It enables local delivery of cell and gene-based therapies, including BioCardia&#8217;s own cell therapies. It remains the safest, easiest to use, and most efficient means for the delivery of cells, genes, and proteins to the heart muscle. The delivery platform includes proprietary approved steerable guide systems, approved delivery catheters, and investigational imaging navigation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company&#8217;s Helix team has active discussions with current and prospective partners regarding programs utilizing the Helix platform. These relationships are intended to share the costs of ongoing maintenance of and advances in the valuable enabling platform, and for BioCardia shareholders to benefit from the future success of these partnered programs.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Intellectual Property</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In June, the Company announced that the Japan Patent Office granted Patent No: JP7282649B2 titled &#8220;Radial and Transendocardial Delivery Catheter&#8221; with a patent term that will expire on September 30, 2034. The patent describes interventional biotherapeutic delivery catheters to deliver biologics to specific target sites from within the heart chamber.&nbsp; The allowed claims cover BioCardia&#8217;s helical needle tipped catheter technology platform in existing products and in future products in active development with enhanced features.&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Also in June, the European Patent Office issued an Intention to Grant a patent titled: &#8220;Site Selection, Entry, And Update with Automatic Remote Inage Annotation.&#8221; The patent application describes techniques to bring previously obtained high-resolution three dimensional images of a patient's heart, such as from an MRI into the cardiac catheterization procedure suite, and to merge this image with the X-ray images that the physician uses to navigate during the procedure. This approach has been compelling in preclinical studies and is expected to further enhance targeting, ease of procedure, and data collection compared to our current procedures.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Second Quarter 2023 Financial Results:</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&gt;</p>
			</td>
			<td style="vertical-align:top;">Revenues were approximately $43,000 for the three months ended June 2023, compared to approximately $974,000 in the three months ended June 2022, due primarily to the timing of collaboration agreement revenues.</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&gt;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Research and development expenses were approximately $2.3 million for the three months ended June 2023 and for the three months ended June 2022.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&gt;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Selling, general and administrative expenses were approximately $1.2 million for the three months ended June 2023 and for the three months ended June 2022.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&gt;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our net loss was approximately $3.4 million for the three months ended June 2023, compared to approximately $2.5 million for the three months ended June 2022, due primarily to the timing of collaboration agreement revenues.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&gt;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net cash used in operations for the three months ended June 2023 was approximately $3.2 million, as compared to approximately $2.6 million for the three months ended June 2022.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;text-indent:-18pt;"><b>ANTICIPATED UPCOMING MILESTONES AND EVENTS:</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&gt;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">BCDA-01: CardiAMP Cell Therapy for Heart Failure Phase III Trial</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:59pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">-</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Q3 2023: Finalize External Review of Interim Data and DSMB Recommendation</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:59pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">-</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Q4 2023: Japan PMDA Formal Consultation</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&gt;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">BCDA-02: CardiAMP Cell Therapy for Chronic Myocardial Ischemia Phase III Trial</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:59pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">-</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Q4 2023: Completion of Roll-in Cohort and Transition to Randomized Pivotal Trial</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&gt;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">BCDA-03: NK1R+ MSC Allogeneic Cell Therapy in ischemic HFrEF Phase I/II Trial</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:59pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">-</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Q3 2023: First Patient Enrolled</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&gt;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Helix Biotherapeutic Delivery System</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:59pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">-</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Q4 2023 Completion of Enrollment in Partner CellProthera&#8217;s EXCELLENT Trial</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:59pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">-</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Q4 2023: Update on Licensing / Partnerships</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>About BioCardia</b>&#174;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">B<u>ioCardia, Inc.</u>, headquartered in Sunnyvale, California, is a developer of two biotherapeutic platforms &#8211; the CardiAMP&nbsp;autologous bone marrow derived mononuclear cell therapy for cardiovascular indications, and the NK1R+ allogeneic bone marrow derived mesenchymal stem cell therapy for cardiovascular and pulmonary diseases.&nbsp;These platforms underly four product candidates, each with the potential to meaningfully benefit millions of patients. Three of BioCardia&#8217;s investigational therapies are enabled by the Company&#8217;s proprietary biotherapeutic delivery platform, which the Company also selectively licenses to other biotherapeutic development firms. The CardiAMP Cell Therapy Trial for Heart Failure has been supported financially by the Maryland Stem Cell Research Fund and the Center for Medicare and Medicaid Services.&nbsp; For more information visit: <u>www.BioCardia.com</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Conference call access:</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Participants can register for the conference by navigating to <u>https://dpregister.com/sreg/10181574/fa1ff8fef0</u>.&nbsp; Please note that registered participants will receive their dial-in number upon registration.&nbsp; For those who have not registered, to listen to the call by phone, interested parties within the U.S. should call 1-833-316-0559 and international callers should call 1-412-317-5730. All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the BioCardia call. The conference call will also be available through a live webcast, which can be accessed through the following link: <u>https://event.choruscall.com/mediaframe/webcast.html?webcastid=IBDjLUv7</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A webcast replay of the call will be available approximately one hour after the end of the call through November 9, 2023, at the above links. A telephonic replay of the call will be available through August 23, 2023 and may be accessed by calling 1-877-344-7529 (domestic), 1-412-317-0088 (international) or 855-669-9658 (Canada) by using access code 7514640 or by the link: <u>https://event.choruscall.com/mediaframe/webcast.html?webcastid=IBDjLUv7</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Forward Looking Statements </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include, among other things, references to the enrollment in our clinical trials, the availability of data from our clinical trials, filings and communications with the FDA and Japan&#8217;s Pharmaceutical and Medical Device Agency, FDA and Japanese product clearances, the efficacy and safety of our products and therapies, preliminary conclusions about new data, the achievement of any of the anticipated upcoming milestones, our positioning for growth or the market for our products and therapies, the expected benefits of our intellectual property, the future prospects for BCDA-01 and the regulatory timeline and process associated with such trial, and other statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations. Such risks and uncertainties include, among others, the inherent uncertainties associated with developing new products or technologies, regulatory approvals, unexpected expenditures, the ability to raise the additional funding needed to continue to pursue BioCardia&#8217;s business and product development plans, the ability to enter into licensing and partnering arrangements and overall market conditions.&nbsp;We may find it difficult to enroll patients in our clinical trials due to many factors, some of which are outside of our control. Slower than targeted enrollment could delay completion of our clinical trials and delay or prevent development of our therapeutic candidates. These forward-looking statements are made as of the date of this press release, and BioCardia assumes no obligation to update the forward-looking statements.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We may use terms such as &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;approximately&#8221; or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release. As a result of these factors, we cannot assure you that the forward-looking statements in this press release will prove to be accurate. Additional factors that could materially affect actual results can be found in BioCardia&#8217;s Form 10-K filed with the Securities and Exchange Commission on March 29, 2023, under the caption titled &#8220;Risk Factors,&#8221; and in our subsequently filed Quarterly Reports on Form 10-Q. BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.&nbsp;&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">###</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Media Contact: </b><br>
Miranda Peto, Marketing / Investor Relations<br>
Email:&nbsp;<u>mpeto@BioCardia.com</u><br>
Phone: 650-226-0120</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Investor Contact: </b><br>
David McClung, Chief Financial Officer<br>
Email:&nbsp;<u>investors@BioCardia.com</u><br>
Phone: 650-226-0120</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>BioCardia, Inc.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Condensed Consolidated Statements of Operations </b><br>
<b>(Unaudited in thousands, except share and per share amounts)</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Three Months ended</b><br>
			<b>June 30,</b></b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D5" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="6" id=".amt.D5" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Six Months ended</b><br>
			<b>June 30,</b></b></b></p>
			</td>
			<td id=".trail.D5" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2023</b></b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2022</b></b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D4" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D4" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2023</b></b></b></p>
			</td>
			<td id=".trail.D4" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D5" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D5" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2022</b></b></b></p>
			</td>
			<td id=".trail.D5" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 52%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Revenue:</p>
			</td>
			<td id=".lead.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B4" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B4" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B4" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B5" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B5" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B5" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B5" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Net product revenue</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Collaboration agreement revenue</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">43</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">974</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">107</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,033</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;">Total revenue</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">43</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">974</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">107</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,034</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Costs and expenses:</p>
			</td>
			<td id=".lead.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B4" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B4" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B4" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B5" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B5" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B5" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B5" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Research and development</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,314</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,304</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,698</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,490</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Selling, general and administrative</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,181</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,166</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,371</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,367</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;">Total costs and expenses</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,495</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,470</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,069</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,857</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;">Operating loss</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,452</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,496</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td id=".lead.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6,962</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td id=".lead.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(5,823</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Other income (expense):</p>
			</td>
			<td id=".lead.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B4" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B4" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B4" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B5" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B5" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B5" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B5" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;">Total other income (expense), net</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">28</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td id=".lead.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">37</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(3,424</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(2,497</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td id=".lead.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(6,925</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td id=".lead.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(5,822</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2" style="padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.B2" style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.B2" style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".trail.B2" style="padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.B3" style="padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.B3" style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.B3" style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".trail.B3" style="padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.B4" style="padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.B4" style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.B4" style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".trail.B4" style="padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.B5" style="padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.B5" style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.B5" style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".trail.B5" style="padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss per share, basic and diluted</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.17</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.14</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td id=".lead.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.34</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td id=".lead.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.34</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
			<td id=".lead.B4">&nbsp;</td>
			<td id=".symb.B4">&nbsp;</td>
			<td id=".amt.B4">&nbsp;</td>
			<td id=".trail.B4">&nbsp;</td>
			<td id=".lead.B5">&nbsp;</td>
			<td id=".symb.B5">&nbsp;</td>
			<td id=".amt.B5">&nbsp;</td>
			<td id=".trail.B5">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Weighted-average shares used in computing net loss per share, basic and diluted</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20,384,522</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">17,651,892</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20,281,417</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">17,360,598</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:bottom;width:65.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>BioCardia, Inc.</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:65.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Selected Balance Sheet Data </b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:65.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(amounts in thousands)</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>June 30,</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b>December 31,</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2023<sup style="vertical-align:top;line-height:120%;">(1)</sup></b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022<sup style="vertical-align:top;line-height:120%;">(1)</sup></b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 70%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Assets:</b></p>
			</td>
			<td id=".lead.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: Times New Roman; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B2" style="font-family: Times New Roman; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B2" style="font-family: Times New Roman; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".lead.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: Times New Roman; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B3" style="font-family: Times New Roman; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B3" style="font-family: Times New Roman; font-size: 10pt;"><b>&nbsp;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash and cash equivalents</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,305</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,363</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Other current assets</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">345</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">501</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Property, equipment and other noncurrent assets</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,739</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,929</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total assets</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,389</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,793</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Liabilities and Stockholders</b>&#8217;<b> Equity</b></p>
			</td>
			<td id=".lead.B2" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: Times New Roman; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B2" style="font-family: Times New Roman; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B2" style="font-family: Times New Roman; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".lead.B3" style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: Times New Roman; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B3" style="font-family: Times New Roman; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B3" style="font-family: Times New Roman; font-size: 10pt;"><b>&nbsp;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Current liabilities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,616</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,585</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease liability - noncurrent</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,138</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,316</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total stockholders&#8217; equity</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,635</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,892</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total liabilities and stockholders&#8217; equity</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,389</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,793</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td colspan="6" style="vertical-align:top;width:98.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(1)&nbsp;&nbsp;June 30, 2023 amounts are unaudited. December 31, 2022 amounts were derived from the audited Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2022, filed with the U.S. Securities and Exchange Commission on March 29, 2023.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>bcda-20230809.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 8/9/2023 2:15:18 AM-->
<xsd:schema xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:bcda="http://www.bcda.com/20230809" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.bcda.com/20230809">
<xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
<xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd"/>

<xsd:annotation>
<xsd:appinfo>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcda-20230809_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcda-20230809_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcda-20230809_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
<link:roleType id="statement-document-and-entity-information" roleURI="http://www.bcda.com/20230809/role/statement-document-and-entity-information">
<link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:presentationLink</link:usedOn>
</link:roleType>
</xsd:appinfo>
</xsd:annotation>
<xsd:element abstract="true" id="bcda_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
<xsd:element abstract="true" id="bcda_CommonStockParValue0001CustomMember" name="CommonStockParValue0001CustomMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
<xsd:element abstract="true" id="bcda_WarrantToPurchaseCommonStockCustomMember" name="WarrantToPurchaseCommonStockCustomMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>bcda-20230809_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 8/9/2023 2:15:18 AM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
<link:roleRef roleURI="http://www.bcda.com/20230809/role/statement-document-and-entity-information" xlink:href="bcda-20230809.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:definitionLink xlink:role="http://www.bcda.com/20230809/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
<link:loc xlink:href="bcda-20230809.xsd#bcda_CommonStockParValue0001CustomMember" xlink:label="bcda_CommonStockParValue0001CustomMember" xlink:type="locator"/>
<link:loc xlink:href="bcda-20230809.xsd#bcda_WarrantToPurchaseCommonStockCustomMember" xlink:label="bcda_WarrantToPurchaseCommonStockCustomMember" xlink:type="locator"/>
<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
<link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
<link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>

<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>

<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bcda_CommonStockParValue0001CustomMember" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bcda_WarrantToPurchaseCommonStockCustomMember" xlink:type="arc"/>

<link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>bcda-20230809_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 8/9/2023 2:15:18 AM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
<link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Type</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Period End Date</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Registrant Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Incorporation, State or Country Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, File Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Tax Identification Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Address Line One</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, City or Town</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, State or Province</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Postal Zip Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:label xlink:label="dei_WrittenCommunications-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:label xlink:label="dei_SolicitingMaterial-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementIssuerTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Emerging Growth Company</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Central Index Key</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
<link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
<link:label xlink:label="us-gaap_ClassOfStockDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain-label" xlink:type="arc"/>

<link:loc xlink:href="bcda-20230809.xsd#bcda_CommonStockParValue0001CustomMember" xlink:label="bcda_CommonStockParValue0001CustomMember" xlink:type="locator"/>
<link:label xlink:label="bcda_CommonStockParValue0001CustomMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CommonStockParValue0001 Custom [Member]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcda_CommonStockParValue0001CustomMember" xlink:to="bcda_CommonStockParValue0001CustomMember-label" xlink:type="arc"/>

<link:loc xlink:href="bcda-20230809.xsd#bcda_WarrantToPurchaseCommonStockCustomMember" xlink:label="bcda_WarrantToPurchaseCommonStockCustomMember" xlink:type="locator"/>
<link:label xlink:label="bcda_WarrantToPurchaseCommonStockCustomMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">WarrantToPurchaseCommonStock Custom [Member]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcda_WarrantToPurchaseCommonStockCustomMember" xlink:to="bcda_WarrantToPurchaseCommonStockCustomMember-label" xlink:type="arc"/>


</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>bcda-20230809_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 8/9/2023 2:15:18 AM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.bcda.com/20230809/role/statement-document-and-entity-information" xlink:href="bcda-20230809.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:presentationLink xlink:role="http://www.bcda.com/20230809/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
<link:loc xlink:href="bcda-20230809.xsd#bcda_CommonStockParValue0001CustomMember" xlink:label="bcda_CommonStockParValue0001CustomMember" xlink:type="locator"/>
<link:loc xlink:href="bcda-20230809.xsd#bcda_WarrantToPurchaseCommonStockCustomMember" xlink:label="bcda_WarrantToPurchaseCommonStockCustomMember" xlink:type="locator"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="bcda_CommonStockParValue0001CustomMember" xlink:type="arc"/>
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="bcda_WarrantToPurchaseCommonStockCustomMember" xlink:type="arc"/>

<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>

<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140370195213424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Aug. 09, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity, Registrant Name</a></td>
<td class="text">BIOCARDIA, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document, Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document, Period End Date</a></td>
<td class="text">Aug.  09,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity, Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity, File Number</a></td>
<td class="text">0-21419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity, Tax Identification Number</a></td>
<td class="text">23-2753988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity, Address, Address Line One</a></td>
<td class="text">320 Soquel Way <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity, Address, City or Town</a></td>
<td class="text">Sunnyvale<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity, Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity, Address, Postal Zip Code</a></td>
<td class="text">94085<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">226-0120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity, Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity, Central Index Key</a></td>
<td class="text">0000925741<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bcda_CommonStockParValue0001CustomMember', window );">CommonStockParValue0001 Custom [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BCDA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bcda_WarrantToPurchaseCommonStockCustomMember', window );">WarrantToPurchaseCommonStock Custom [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrant to Purchase Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BCDAW<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bcda_CommonStockParValue0001CustomMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bcda_CommonStockParValue0001CustomMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bcda_WarrantToPurchaseCommonStockCustomMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bcda_WarrantToPurchaseCommonStockCustomMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>bcda20230808_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bcda="http://www.bcda.com/20230809"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="bcda-20230809.xsd" xlink:type="simple"/>
    <context id="d20238K">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000925741</identifier>
        </entity>
        <period>
            <startDate>2023-08-09</startDate>
            <endDate>2023-08-09</endDate>
        </period>
    </context>
    <context id="d20238K_StatementClassOfStockAxis_CommonStockParValue0001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000925741</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcda:CommonStockParValue0001CustomMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-09</startDate>
            <endDate>2023-08-09</endDate>
        </period>
    </context>
    <context id="d20238K_StatementClassOfStockAxis_WarrantToPurchaseCommonStock">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000925741</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bcda:WarrantToPurchaseCommonStockCustomMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-09</startDate>
            <endDate>2023-08-09</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="d20238K">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="d20238K">0000925741</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="d20238K">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="d20238K">2023-08-09</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="d20238K">BIOCARDIA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="d20238K">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="d20238K">0-21419</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="d20238K">23-2753988</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d20238K">320 Soquel Way </dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d20238K">Sunnyvale</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d20238K">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d20238K">94085</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d20238K">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d20238K">226-0120</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="d20238K">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="d20238K">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="d20238K">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="d20238K">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="d20238K_StatementClassOfStockAxis_CommonStockParValue0001">Common Stock, par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d20238K_StatementClassOfStockAxis_CommonStockParValue0001">BCDA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d20238K_StatementClassOfStockAxis_CommonStockParValue0001">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="d20238K_StatementClassOfStockAxis_WarrantToPurchaseCommonStock">Warrant to Purchase Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d20238K_StatementClassOfStockAxis_WarrantToPurchaseCommonStock">BCDAW</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d20238K_StatementClassOfStockAxis_WarrantToPurchaseCommonStock">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="d20238K">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    (  .!"5<'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  #@0E7DI.^&>X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M:L,P#(9?9?B>R$E@=";UI:.G#@8K;.QF;+4UBQUC:R1]^SE9FS*V!]C1TN]/
MGT"M#D+W$9]C'S"2Q70WNLXGH<.:G8B" $CZA$ZE,B=\;A[ZZ!3E9SQ"4/I#
M'1%JSN_!(2FC2,$$+,)"9+(U6NB(BOIXP1N]X,-G[&:8T8 =.O24H"HK8'*:
M&,YCU\(-,,$(HTO?!30+<:[^B9T[P"[),=DE-0Q#.31S+N]0P=O3[F5>M[ ^
MD?(:\Z]D!9T#KMEU\FNS>=QOF:QYW11\5?"'?<T%7PE>O4^N/_QNPJXW]F#_
ML?%54+;PZR[D%U!+ P04    "  #@0E7F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M  .!"5?\1%G_V00  &05   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MM9AA;^HV%(;_BI5-TR;1DCA H0,D2ML-W=N6%78K[6H?3&+ NHF=ZSBE_/L=
M!YHPW7!"*[4?2@+QFR<^Y[PG=G^C]+=TS;DA+W$DTX&S-B:Y;#;38,UCEIZK
MA$OX9:ETS R<ZE4S331G83XHCIK4=3O-F GI#/OY=U,][*O,1$+RJ29I%L=,
M;Z]XI#8#QW->OW@4J[6Q7S2'_82M^(R;OY.IAK-FH1**F,M4*$DT7PZ<D7=Y
MY><#\BN^"+Y)#XZ)?92%4M_LR20<.*XEXA$/C)5@\/',QSR*K!)P?-^+.L4]
M[<##XU?UV_SAX6$6+.5C%3V)T*P'3M<A(5^R+#*/:O,GWS]0V^H%*DKS_V2S
MN[;5=DB0I4;%^\% $ NY^V0O^XDX&.#[1P;0_0":<^]NE%->,\.&?:TV1-NK
M0<T>Y(^:CP8X(6U49D;#KP+&F>&U"C*89$-&,B0WT@BS)1.YBS;,6K]IX";V
MTF:P%[S:"=(C@J-L=4[<7H-0E_K_']X$M@*0%H TU_/K  ^HR-?/<!69&!ZG
M_U8A[B1;U9(VT2_3A 5\X$ FIUP_<V?XRT]>Q_T= ?8+8!]3'^XFL4$>^4JD
M1C- OV<QK\+$A:XF#^/1X_5DU""3^_$Y@M8JT%JHXNM<-LA\FU02X>.[9Y\0
MBG9!T3Z18LJU4#;M0@+)6PF$2^7)EF=;7;IU"KC.2=&;R$#I1.D\WQID9H"/
M*$W&*I-&;^$SK.3%U:]O$,2+ O'B),1;$7%RG\4+KJM(<!'WC'HMKX?@= N<
M[DDX<_9")B'$52Q%L"O3XW"X)/7/Z$7;[W6["%^OX.N=Q#<*0RCVM#@@N8<\
MR,HPHI+5!N)3E\S4]XQ'Y(EM"4+NN:4YNV]C'UM_AC2<JTVU-^-ZLTS*[3.+
M.$9WT#J\M]$553+5ZEG(H')J:T3'(XRM[!H>ZO$_LDU5:EA$_A')T=JMD>RU
MW&X;@RL[A(<[>Q[%$;Q$'4?!!3IM%P,I^X&'&_IG%<"<3-=*8DY2(T)IY\SU
M*$I4]@8/=_0G+8SA$B8FCC.Y-Y*TD@H76K(H1=.\[ @>;MHS%8E &"%7Y [R
M6PL65?+@*K4\I?U[N'5/-3\+8'HX%%C^9C3G,N2:/"R71^*'Z]62E9W PWW[
M![))FF9 5@N(R]8"EJW .ZT7W,1<KVQ _P )L[;9EC"YK63#%>O8:.GU%/?F
M$<Q8F,_:;<16E6^UN$ M2FGL]#1C'P.-!H.80/A>R"=>.4$U6B[\]6C[HN5A
M: >K =R$K2\H.3,J^#9E^@N+,@XW\,@X7RJ1KW?<NECUHN C5@6T-'WJ?\!"
M!NT#[V4N^P/%K7TN#+QCJB7QZ*^+W\B,!QGX<W4:X$J[N)$\< V2,$V>;>S(
MS^XYA ^#+5L'Q1U_KEEH:WJVC1>JTJ)K!*[&U]C+!RT[!JWI&/MY(C<OP9K)
M%3^Z JP1NA_-KD=_84QEUZ"XRS\Q;=>B<S7--$#9?8RBDDZJ'E3^O9E8MA;:
M_8#J0?O*>YG+;D/QWO"6ZL&5]L$C1I'7\)'#BL*V+<H&Y./]H[Y^:@1L_3QA
M*&4#\O&F<7H!U0@=+Z#FP9Z9W7^\8_:-("417X*2>WX!7J%W6WJ[$Z.2?!MM
MH0S42GZXY@S>:^P%\/M2*?-Z8G?FBHW5X7]02P,$%     @  X$)5Y^@&_"Q
M @  X@P   T   !X;"]S='EL97,N>&ULW5=M:]LP$/XK0C]@;F)JXI$8MD!A
ML(U"\V%?E5AV!'KQ9+ES^NNGLVPG:75EW8>QS:')W3VZNT=W)YFN6W>2_.'(
MN2.]DKK=T*-SS?LD:0]'KEC[SC1<>Z0R5C'G55LG;6,Y*UMP4C)9WMQDB6)"
MTV*M.W6G7$L.IM-N0V]H4JPKH\^6E :#7\H4)X],;NB62;&W8EC+E)"G8%Z"
MX6"DL<1Y*GQ#%V!IGP*\"!JP'.,HH8T%8Q(RA._]N/P9,&FM5X64,\$E#89B
MW3#GN-5W7AD6#\87$!GEW:GQ#&O+3HOE+3T[##\^R=[8DMLYS8).IF(M>05T
MK*B/\.M,DP#HG%%>* 6KC68#A\EC%'S8 Y?R 5KXK;J*W5<D].)3"6T@L-5)
M](1&,80)"L2_C!9B7X2]_:VPI!&/QGWL_&[TH'_OC./WEE>B'_2^FO-CT1=X
M=-8T\O1!BEHK'O;^RPF+-9O\R-%8\>2SP:0<O(%;2AZY=>)P:?EA6;/CO9NF
MJ:]PSLM_D/.?K7/--;=,7I+VH_\W5_DMC)/Q]%P<T:L#.EL)7(0;^A7N5WGF
M0/:=D$[H43N*LN3ZQ3GUX1W;^PO\*KY?7_**==+M9G!#S_(77HI.Y?.J>ZC+
MN.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<<GB-WPQ-',)^ Q1' L#P8
M \PG>&%Y_J?]K-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\3;,,J^AV
M&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4KS4@\;J!
M1Y['NXWE 0^L"]CL0/YX'IBIN$^:0E<Q;M@)QI$\QQ"8Q?B,9AE2G0P^\?Y@
MIR1-\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%
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MR3J)T]UY<:*X+XGVZLN[D K=,+?S+$M5 ]ZD*VHAR*2FZ U+&W=9:B,8FQH
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M8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @  X$)5YE<G",0!@  G"<  !,
M             ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M"  #@0E7_$19_]D$  !D%0  &               @($-"   >&PO=V]R:W-H
M965T<R]S:&5E=#$N>&UL4$L! A0#%     @  X$)5Y^@&_"Q @  X@P   T
M             ( !' T  'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  #@0E7
MEXJ[',     3 @  "P              @ 'X#P  7W)E;',O+G)E;'-02P$"
M% ,4    "  #@0E7.JJBYT !   \ @  #P              @ 'A$   >&PO
M=V]R:V)O;VLN>&UL4$L! A0#%     @  X$)5R0>FZ*M    ^ $  !H
M         ( !3A(  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#
M%     @  X$)5V60>9(9 0  SP,  !,              ( !,Q,  %M#;VYT
D96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  ?10

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="bcda20230808_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bcda.com/20230809/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="bcda20230808_8k.htm">bcda20230808_8k.htm</File>
    <File>bcda-20230809.xsd</File>
    <File>bcda-20230809_def.xml</File>
    <File>bcda-20230809_lab.xml</File>
    <File>bcda-20230809_pre.xml</File>
    <File>ex_557356.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="25">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "bcda20230808_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 1,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 25
   },
   "contextCount": 3,
   "dts": {
    "definitionLink": {
     "local": [
      "bcda-20230809_def.xml"
     ]
    },
    "inline": {
     "local": [
      "bcda20230808_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "bcda-20230809_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bcda-20230809_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "bcda-20230809.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    }
   },
   "elementCount": 30,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2023": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 2,
   "memberStandard": 0,
   "nsprefix": "bcda",
   "nsuri": "http://www.bcda.com/20230809",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bcda20230808_8k.htm",
      "contextRef": "d20238K",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.bcda.com/20230809/role/statement-document-and-entity-information",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bcda20230808_8k.htm",
      "contextRef": "d20238K",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 2,
   "tag": {
    "bcda_CommonStockParValue0001CustomMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CommonStockParValue0001 Custom [Member]"
       }
      }
     },
     "localname": "CommonStockParValue0001CustomMember",
     "nsuri": "http://www.bcda.com/20230809",
     "presentation": [
      "http://www.bcda.com/20230809/role/statement-document-and-entity-information"
     ],
     "xbrltype": "domainItemType"
    },
    "bcda_WarrantToPurchaseCommonStockCustomMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WarrantToPurchaseCommonStock Custom [Member]"
       }
      }
     },
     "localname": "WarrantToPurchaseCommonStockCustomMember",
     "nsuri": "http://www.bcda.com/20230809",
     "presentation": [
      "http://www.bcda.com/20230809/role/statement-document-and-entity-information"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.bcda.com/20230809/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.bcda.com/20230809/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.bcda.com/20230809/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document, Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.bcda.com/20230809/role/statement-document-and-entity-information"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document, Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.bcda.com/20230809/role/statement-document-and-entity-information"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity, Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.bcda.com/20230809/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity, Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.bcda.com/20230809/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity, Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.bcda.com/20230809/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity, Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.bcda.com/20230809/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity, Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.bcda.com/20230809/role/statement-document-and-entity-information"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.bcda.com/20230809/role/statement-document-and-entity-information"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity, Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.bcda.com/20230809/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity, File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.bcda.com/20230809/role/statement-document-and-entity-information"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity, Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.bcda.com/20230809/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity, Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.bcda.com/20230809/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity, Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.bcda.com/20230809/role/statement-document-and-entity-information"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.bcda.com/20230809/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.bcda.com/20230809/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.bcda.com/20230809/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.bcda.com/20230809/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.bcda.com/20230809/role/statement-document-and-entity-information"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.bcda.com/20230809/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.bcda.com/20230809/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.bcda.com/20230809/role/statement-document-and-entity-information"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.bcda.com/20230809/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.bcda.com/20230809/role/statement-document-and-entity-information"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.bcda.com/20230809/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001437749-23-022787-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-23-022787-xbrl.zip
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M_R99KDHFY'\<XU],:R;M@[ISFF^P]#N1# 5Z /['1DMW_ZTX_1=02P,$%
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MI:IL?N//R'+J:):ORAV LZP])HU_OX.O^\"7WNQ7!>E_V<'7_ =02P,$%
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ML^B>'?V[%M7TEJ;#A$GO%8]ZFD6WU=,><J7SNO*0(C6Z04AP:TRAQ/%KVP/
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M$IO\B_B@EE^:DIQ+<G[ <*X52%*.3E_;;#Q5?N%6S*?L1JU94G9)V<M'V5\
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MU)A^?Q>DKGMX!QY8Z[9$SHR<4'6(@BA3#7V*:#'W$I%XQ"JL'NX@7>4 U*Z
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M/9562NBW#-"O$&(I (.5*.\-H+Q"B.5M>.O>+:";*5N*!W2/(Y<?S ](KK]
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MA$/GX/\!4$L! A0#%     @  X$)5Y0-X0"H P  /P\  !$
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M4$L! A0#%     @  X$)5Y4&ICFJ#P  PFD  !,              ( !P!4
M &)C9&$R,#(S,#@P.%\X:RYH=&U02P$"% ,4    "  #@0E7X18':I4J  !L
M<P$ #0              @ &;)0  97A?-34W,S4V+FAT;5!+!08     !@ &
+ (0!  !;4      !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
